These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 33626287)

  • 1. Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists.
    Gill L; Mackey S
    J Womens Health (Larchmt); 2021 Jul; 30(7):1016-1027. PubMed ID: 33626287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
    Ard J; Fitch A; Fruh S; Herman L
    Adv Ther; 2021 Jun; 38(6):2821-2839. PubMed ID: 33977495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity.
    Patel D; Smith A
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1193-1204. PubMed ID: 34231442
    [No Abstract]   [Full Text] [Related]  

  • 6. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers.
    Fitch A; Ingersoll AB
    Postgrad Med; 2021 Apr; 133(3):310-319. PubMed ID: 33151791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity.
    Jensterle M; Janež A
    Horm Res Paediatr; 2023; 96(6):599-608. PubMed ID: 34852347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide in the treatment of obesity.
    Ng SY; Wilding JP
    Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.
    Giannakogeorgou A; Roden M
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S52-S75. PubMed ID: 38813830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity Management in Adults: A Review.
    Elmaleh-Sachs A; Schwartz JL; Bramante CT; Nicklas JM; Gudzune KA; Jay M
    JAMA; 2023 Nov; 330(20):2000-2015. PubMed ID: 38015216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.
    Taha MB; Yahya T; Satish P; Laird R; Agatston AS; Cainzos-Achirica M; Patel KV; Nasir K
    Curr Atheroscler Rep; 2022 Aug; 24(8):643-654. PubMed ID: 35624390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Christensen RM; Juhl CR; Torekov SS
    Drug Saf; 2019 Aug; 42(8):957-971. PubMed ID: 30972641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
    Guyton J; Jeon M; Brooks A
    Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity.
    Burcelin R; Gourdy P
    Obes Rev; 2017 Jan; 18(1):86-98. PubMed ID: 27636208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review.
    Jensterle M; Rizzo M; Haluzík M; Janež A
    Adv Ther; 2022 Jun; 39(6):2452-2467. PubMed ID: 35503498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist.
    Iepsen EW; Zhang J; Thomsen HS; Hansen EL; Hollensted M; Madsbad S; Hansen T; Holst JJ; Holm JC; Torekov SS
    Cell Metab; 2018 Jul; 28(1):23-32.e3. PubMed ID: 29861388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity.
    Yazıcı D; Yapıcı Eser H; Kıyıcı S; Sancak S; Sezer H; Uygur M; Yumuk V
    Obes Facts; 2023; 16(2):149-163. PubMed ID: 36349778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity.
    Lin CH; Shao L; Zhang YM; Tu YJ; Zhang Y; Tomlinson B; Chan P; Liu Z
    Expert Opin Pharmacother; 2020 Feb; 21(3):275-285. PubMed ID: 31790314
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.